Stephen George Dilly
Known title: DirectorCIK: 0001389147
Stephen George Dilly's purchase track record
Stephen George Dilly has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/8/2023 | CDXS | $101K | +32.6% | +101.7% | +14.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CDXS | ▲ Buy | Grant | 50,000 | $92K | 11/11/2025 | View on chart |
| CDXS | ▲ Buy | Grant | 88,750 | $0 | 2/5/2025 | View on chart |
| CDXS | ▲ Buy | Grant | 143,425 | $0 | 1/1/2024 | View on chart |
| CDXS | ▲ Buy | Open Market | 58,479 | $101K | 9/8/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 26,987 | $123K | 3/8/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 28,088 | $129K | 3/7/2023 | View on chart |
| CDXS | ▲ Buy | Grant | 112,500 | $0 | 2/21/2023 | View on chart |
| CDXS | ▲ Buy | Grant | 289,000 | $0 | 2/8/2023 | View on chart |
| CDXS | ▲ Buy | Grant | 11,273 | $0 | 6/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Codexis Signs siRNA Manufacturing Deal
Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.
Codexis Signs siRNA Manufacturing Deal. Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.